Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + oxaliplatin + S-1 + trastuzumab
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial People's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A systemic combination therapy regimen consisting of tislelizumab, oxaliplatin, S-1, and trastuzumab. This regimen is being investigated by The First Affiliated Hospital with Nanjing Medical University as a conversion therapy for patients with gastric or esophagogastric junction cancer presenting with peritoneal metastasis. The protocol involves the use of the PD-1 inhibitor tislelizumab to stimulate the immune system, the SOX chemotherapy doublet (oxaliplatin and S-1) for cytotoxic effect, and the HER2-targeted antibody trastuzumab for patients with HER2-positive tumors. It is typically evaluated in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) as part of a multimodal treatment strategy to improve R0 resection rates and overall survival in advanced gastric malignancies.
- Other names
- Tislelizumab + SOX + TrastuzumabPD-1 + SOX + HerceptinTislelizumab + Oxaliplatin + S-1 + Trastuzumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA
Beyond the preview
Go deeper on tislelizumab + oxaliplatin + S-1 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + oxaliplatin + S-1 + trastuzumab.